Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine by Krittaecho Siripassorn et al.
Siripassorn et al. AIDS Research and Therapy 2013, 10:4
http://www.aidsrestherapy.com/content/10/1/4RESEARCH Open AccessVirological failure of staggered and simultaneous
treatment interruption in HIV patients who began
Efavirenz-based regimens after allergic reactions
to nevirapine
Krittaecho Siripassorn1*, Weerawat Manosuthi1, Aranya Pakdee1, Sunanta Natprom1, Anuttra Chaovavanich1,
Narongsak Hengphadpanadamrong1, Khobchok Woratanarat1, Aroon Lueangniyomkul1, and Kiat Ruxrungtham2
on behalf of the Bamrasnaradura study teamAbstract
Objective: The objective of this work was to study the virological outcomes associated with two different types of
treatment interruption strategies in patients with allergic reactions to nevirapine (NVP). We compared the virological
outcomes of (1) HIV-1-infected patients who discontinued an initial NVP-based regimen because of cutaneous
allergic reactions to NVP; different types of interruption strategies were used, and second-line regimen was based
on efavirenz (EFV); and (2) HIV-1-infected patients who began an EFV-based regimen as a first-line therapy
(controls).
Methods: This retrospective cohort included patients who began an EFV-based regimen, between January 2002
and December 2008, as either an initial regimen or as a subsequent regimen after resolving a cutaneous allergic
reaction against an initial NVP-based regimen. The study ended in March 2010. The primary outcome was
virological failure, which was defined as either (a) two consecutive plasma HIV-1 RNA levels >400 copies/mL or
(b) a plasma HIV-1 RNA level >1,000 copies/mL plus any genotypic resistance mutation.
Results: A total of 559 patients were stratified into three groups: (a) Simultaneous Interruption, in which the
subjects simultaneously discontinued all the drugs in an NVP-based regimen following an allergic reaction (n=161);
(b) Staggered Interruption, in which the subjects discontinued NVP treatment while continuing nucleoside reverse
transcriptase inhibitor (NRTI) backbone therapy for a median of 7 days (n=82); and (c) Control, in which the subjects
were naïve to antiretroviral therapy (n=316). The overall median follow-up time was 43 months. Incidence of
virological failure in Simultaneous Interruption was 12.9 cases per 1,000 person-years, which trended toward being
higher than the incidences in Staggered Interruption (5.4) and Control (6.6). However, differences were not
statistically significant.
Conclusions: Among the patients who had an acute allergic reaction to first-line NVP-based therapy and later
began an EFV-based regimen, virological outcomes resulting from a staggered interruption of treatment (with a
continuation of NRTI backbone therapy for 7 days after discontinuing NVP) did not differ from those of the patients
who began an EFV-based regimen as their initial therapy (Control). However, the virological failure of Simultaneous
Interruption was possibly higher than those of Control and Staggered Interruption.
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Non-nucleoside analog reverse transcriptase inhibitor
(NNRTI)-based regimens are currently recommended as a
first-line therapy for HIV-1-infected patients because of
their virological potency, lower risk of drug interactions
and lower cost, as well as the availability of fixed-dose
combinations. Nevirapine (NVP) is a first-line NNRTI
recommended for antiretroviral-naïve patients, according
to the European AIDS Clinical Society (EACS) guidelines
[1]. NVP is also an acceptable first-line NNRTI for HIV-
1-infected patients, according to the current Department
of Health and Human Services (DHHS) guidelines [2].
NVP retains its usefulness in antiretroviral-naïve patients
due to its lack of teratogenic effects or central nervous sys-
tem toxicity and a lower cost than efavirenz (EFV) (a pre-
ferred initial NNRTI drug). However, one drawback of
NVP is its induction of allergic reactions in approximately
5-14% of users worldwide [3-6]. After discontinuing NVP
because of this allergic reaction, these patients may begin
using other NNRTIs, such as EFV or etravirine (ETR).
Most of these patients continue to take EFV even after the
allergic reaction to NVP is resolved because of the lower
incidence of rash associated with EFV vs. NVP and the re-
quirement of a single daily dose. A recurrent rash has
been described in approximately 12.6% (95% confidence
interval 2.7–22.4%) of HIV-1-infected patients who previ-
ously experienced an allergic reaction to NVP and then
began using EFV [7].
The method of antiretroviral treatment interruption fol-
lowing an allergic reaction to an NNRTI-based regimen is
a major consideration. The simultaneous discontinuation
of all the drugs in a NNRTI-based regimen would result in
a period of functional NNRTI monotherapy; NNRTIs
exhibit a longer plasma half-life and a longer duration of
detectable levels than nucleoside analog reverse transcript-
ase inhibitors (NRTIs) [8]. NNRTIs exhibit a low genetic
barrier to resistance; a single point mutation may lead to
high NVP or EFV resistance [9,10]. As of November 3,
2008, the DHHS guidelines [11] recommend that patients
either first halt the use of NNRTIs and then continue
using NRTIs for a period of time (i.e., staggered interrup-
tion) or switch from an NNRTI-based regimen to a prote-
ase inhibitor (PI)-based regimen before discontinuing
antiretroviral drugs (ARV). The simultaneous interruption
of all the drugs in an NNRTI-based regimen is not recom-
mended because it might induce a resistance mutation.
This guideline is based primarily on clinical studies on the
prevention of mother-to-child transmission [12-14] and
treatment interruption strategies [15].
HIV-1-infected patients with a history of allergic reac-
tions to NVP who plan to begin an EFV-based regimen
may later experience different effects from those asso-
ciated with the prevention of mother-to-child transmis-
sion or with treatment interruption strategies. Thus, weconducted a retrospective cohort study to examine the
effectiveness of different types of treatment interruption
strategies in HIV-1-infected patients who halted an
NVP-based regimen because of cutaneous allergic reac-
tions to NVP and later began an EFV-based regimen.
Methods
Study population
This retrospective cohort study was performed at the
Bamrasnaradura Infectious Diseases Institute, Ministry of
Public Health, Nonthaburi, Thailand. The Simultaneous
Interruption group consisted of HIV-1-infected patients
who simultaneously discontinued the use of all the drugs
in an NVP-based regimen after experiencing a cutaneous
allergic reaction to the treatment. The Staggered Interrup-
tion group consisted of HIV-1-infected patients who first
discontinued the use of NVP after experiencing a cutane-
ous allergic reaction to an NVP-based regimen but who
continued with other NRTIs for several days. The Control
group included patients who began an EFV-based regimen
as first-line therapy and who were never exposed to NVP.
The study end date was March 2010.
A total of 12,803 medical records of HIV-1-infected
patients were retrieved from a medical database and
reviewed (Figure 1). The inclusion criteria were as follows:
(a) documented HIV-1 infection, (b) 18–70 years of age,
(c) began an EFV-based regimen as the initial treatment or
began an EFV-based regimen after the resolution of a cu-
taneous allergic reaction to the initial NVP-based regimen,
and (d) began an EFV-based regimen between January
2002 and December 2008 at the Bamrasnaradura Infec-
tious Diseases Institute. The exclusion criteria were as
follows: (a) previously received a non-HAART regimen,
such as a dual-NRTI regimen or a single-dose NVP with
zidovudine monotherapy, and (b) a history of diseases or
conditions that severely affect either kidney or liver func-
tion, such as decompensated liver cirrhosis or end-stage
renal disease.
The study was approved by the Ethics Committee for
Research in Human Subjects, Department of Disease Con-
trol, Ministry of Public Health, Thailand.
Data collection
Data were collected from the medical records of the
eligible patients. These data included (a) demographic
features, (b) any history of allergic reactions to NVP-
based regimens or other drugs, (c) previous and current
antiretroviral (ARV) regimens, (d) CD4 cell counts and
plasma HIV-1 RNA levels, and (e) both laboratory and
clinical adverse events.
Plasma HIV-1 RNA was initially measured using reverse
transcriptase polymerase chain reaction (RT-PCR) with a
COBAS AMPLICOR HIV-1 MONITOR test, version 1.5
(Roche Molecular Systems, Inc., Branchburg, NJ, USA),
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Figure 1 (See legend on next page.)
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Figure 1 Profile of the study cohort. ART = Antiretroviral therapy; AZT = Zidovudine; D4T = Stavudine; EFV = efavirenz; NVP = Nevirapine;
OBRs = optimized background regimens; TDF = tenofovir; 3TC = lamivudine. aRandom sampling was performed using random numbers.
bHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based regimens when they experienced allergic reactions to
NVP-based regimens. cHIV-1-infected patients who discontinued NVP first but continued use of the other NRTIs for a few days when they
experienced allergic reactions to NVP-based regimens. dThis criterion included patients who changed EFV to other NNRTIs or PIs. It did not
include patients who only changed or modify NRTIs. eVirological failure was defined as either (1) having two consecutive results of plasma HIV-1
RNA >400 copies/ml after 6 month of a EFV-based regimen or (2) having plasma HIV-1 RNA >1,000 copies/ml plus having any genotypic
resistance mutation to efavirenz-based regimen. fIt included either (1) patients who did not have clinical visits for more than 3 months from
appointment date or (2) patients who stopped efavirenz-based regimen for more than 3 months. gThe cohort ended on 31 March 2010.
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of 50–100,000 copies/ml (ultrasensitive technique) or
400–1,000,000 copies/ml (standard technique). After June
2008, plasma HIV-1 RNA levels were evaluated using real-
time PCR with a COBASW AmpliPrep/COBASW Taq-
ManW HIV-1 test (Roche Molecular Systems, Inc.), which
can be used to measure plasma HIV-1 RNA levels in the
range of 40–10,000,000 copies/ml.
Patients who did not appear for clinical visits for more
than 3 months after a missed appointment or who discon-
tinued an EFV-based regimen for more than 3 months
were considered lost to follow-up. Patients who halted an
EFV-based regimen for fewer than 3 months were classi-
fied as having an EFV-based regimen interruption.
We defined an adverse laboratory event as any labora-
tory result of at least a grade 3, according to the Div-
ision of AIDS Table for Grading the Severity of Adult
and Pediatric Adverse Events (the DAIDS AE grading
table). A clinical adverse event was defined as any clin-
ical adverse event that resulted in the physician chan-
ging or modifying the antiretroviral regimen. A patient
was allowed to continue participating in the study if the
physician only changed or modified the NRTIs used. How-
ever, if the physician changed EFV to other NNRTIs or
PIs, the patient was discontinued from the study cohort.
Between January 2010 and March 2010, there was a
final evaluation of the HIV-1-infected patients who con-
tinued an EFV-based regimen through the end of study.
The evaluation consisted of the following: (a) a plasma
HIV-1 RNA assay, (b) a CD4 cell count, (c) a complete
blood count, and (d) blood chemistry tests. Patients
were informed about the evaluation if they (a) came to
the hospital during this period, (b) were continuing an
EFV-based regimen, and (c) did not have the results of
any plasma HIV-1 RNA measurements obtained be-
tween October 1, 2009 and December 31, 2009. At the
end of the study, 381 patients were still participating
(Figure 1). Of these, 205 patients were eligible for the
final evaluation because 176 patients had undergone
plasma HIV-1 RNA assays between October 2009 and
December 2009. There were 201 patients (98%) who
completed the evaluation and provided written informedconsent for the study. The remaining four patients
attended the follow-up examination at the hospital, but we
were unable to contact them concerning the evaluation
and consent form.
Statistical analysis
The primary outcome was virological failure, which was
defined as either (a) two consecutive plasma assay results
indicating HIV-1 RNA levels >400 copies/mL after 6
months of an EFV-based regimen or (b) a single plasma
HIV-1 RNA level >1,000 copies/mL in addition to any
genotypic resistance mutation to an EFV-based regimen.
These criteria included only virological results obtained
after 6 months of an EFV-based regimen. Genotypic resist-
ance mutations were included in the virological criteria to
reduce the bias from viral blips and noncompliance.
The secondary outcomes were as follows: (a) the per-
centage of patients who exhibited virological suppres-
sion; (b) the CD4 cell counts; (c) the clinical outcomes
of death, major opportunistic infection, immune recov-
ery syndrome, and non-AIDS-associated disease; and
(d) adverse laboratory and clinical events.
The relative risk and 95% confidence intervals were
calculated to compare the differences in primary outcome
among the groups. In addition, stratified analysis models
were used to evaluate the effects of confounding factors
on the primary outcome.
Virological suppression was defined as either (a) a plasma
HIV-1 RNA level <50 copies/ml (based on RT-PCR using
the COBAS Amplicor HIV-1 Monitor test, version 1.5) or
(b) a plasma HIV-1 RNA level <40 copies/ml (based on
real-time PCR using the COBASW AmpliPrep/COBASW
TaqManW HIV-1 test).
The baseline characteristics and outcomes were ana-
lyzed with (a) a chi-squared test for dichotomous data,
(b) the Mann–Whitney test or the Kruskal-Wallis test for
continuous data with a non-normal distribution, and
(c) an unpaired t-test and a one-way ANOVA for continu-
ous data with a normal distribution. All the reported
p-values were two-sided and were considered statistically
significant if p<0.05. The analyses were performed using
SPSS version 14.
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Participants and baseline demographic features
Figure 1 presents the profile of the study cohort. There
were 559 patients at the beginning of the study (January
2002) and 381 patients at the end of the study (March
2010).
Among the 139 patients who (a) were lost to follow-
up (n = 53), (b) were referred to other hospitals (n = 50),
(c) experienced a change in therapy from EFV to an-
other ARV (n = 26), and (d) died (n = 10), 104 patients
(74.8%) underwent plasma HIV-1 RNA assays within 6
months before they were removed from the cohort.
Ninety-five of these patients (91.3%) demonstrated viro-
logical suppression.
There were 26 patients in the study (4.7%) whose the-
rapy was changed from EFV to another ARV (another
NNRTI or PI) (Figure 1). This group did not include
patients who (a) received only changes or modifications
to their NRTIs or (b) failed an EFV-based regimen or
experienced EFV toxicity. The main reasons for substi-
tuting another therapy for EFV were financial issues
(35%) and pregnancy (23%).
The baseline demographic features of the patients are
summarized in Table 1. The patients in the Staggered
Interruption group continued using other NRTIs after dis-
continuing NVP for a median (IQR) duration of 7 (6, 9)Table 1 Baseline demographic and clinical characteristics of e
Ava
dat
Total number, n 559
Mean age, years (SD) 559
Female, % 559
Mean body weight, kilograms (SD) 556
History of previous major opportunistic infections, % 556
History of previous allergic reactions to other drugs (exclude NVP), % 555
Median duration of previous NVP-based regimens, days (IQR) 234
Median baseline of CD4 cell count, cells/uL (IQR) e 543







Note: AZT = Zidovudine; D4T = Stavudine; EFV = Efavirenz; IQR = Interquartile rang
deviation; TDF = Tenofovir; 3TC = Lamivudine.
aHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based re
bHIV-1-infected patients who discontinued NVP first but continued use of the other
regimens.
cHIV-1-infected patients who were naïve to antiretroviral therapy and were never ex
dp-value represents the difference between the three groups (Simultaneous interru
eThese results would be included if they were examined within 6 months before stdays. The NRTIs that were most commonly used in the
Staggered Interruption group were stavudine/lamivudine
(d4T/3TC, 73.3%) and zidovudine/lamivudine (AZT/3TC,
23.3%).
Main outcomes
Table 2 summarizes the outcomes of this cohort.
The overall median (IQR) duration of the follow-up
period was 43 (22, 66) months. The Simultaneous Inter-
ruption group had a significantly longer follow-up period
than the other two groups (p<0.001).
There were 27 patients who experienced EFV-based regi-
men interruptions during the study (Table 2). The Simul-
taneous Interruption group had more documented regimen
interruptions than the other two groups (p = 0.007). The
median (IQR) duration of the EFV-based regimen interrup-
tions was 42 (12, 60) days. Common causes of the regimen
interruptions included (a) financial issues (n =7), (b) toxicity
(n = 7), and (c) poor compliance with the medication regi-
men (n = 7). There were 13 patients who discontinued all
ARVs during regimen interruptions, whereas the remaining
patients switched to other therapies, such as PI- or NVP-
based regimens.
The incidence of virological failure was trended toward
being higher in the Simultaneous Interruption group than










41.8 (8.3) 39.4 (9.4) 43.0 (8.4) 0.003
39.1 59.8 33.9 <0.001
54.9 (9.2) 54.8 (9.8) 56.9 (12.4) 0.091
40.6 35.4 51.9 0.007
32.7 30.9 11.4 <0.001
14 (11,27) 14 (12, 30) 0.574
69 (24, 140) 90 (26, 167) 47 (13, 132) 0.006
69.6 77.4 76.0 0.595




e; NVP = Nevirapine; OBRs = Optimized background regimens; SD = Standard
gimens when they experienced allergic reactions to NVP-based regimens.
NRTIs for a few days when they experienced allergic reactions to NVP-based
posed to NVP before beginning EFV-based regimens.
ption, Staggered interruption, and Control).
arting EFV-based regimens.









Total number, n 559 161 82 316
Median duration of EFV-based regimens, months (IQR) 559 57 (27–73) 31 (18–52) 40 (23–65) <0.001
Once-daily regimen at end of study, % 378 66.0 53.7 69.2 0.097
Documented EFV-based regimen interruption, % e 559 9.3 3.7 2.8 0.007
Frequency of plasma HIV-RNA assays 559
> 2 times/year, % 14.9 32.9 22.2 0.030
1–2 times/year, % 57.1 48.8 60.4
< 1 time/year, % 28.0 18.3 17.4
Primary outcome
Incidence of virological failure, cases per 1,000 person-years 559 12.9 5.4 6.6
Relative risk of having virological failure when compared to
Control group, (95% CI)
559 1.97 (0.62–6.38) 0.83 (0.02–6.43)
Secondary outcomes
Virological suppressiong at 24 (±3) months, % (Per-protocol-analysis) 440 66.9 76.9 68.9 0.411
Median CD4 cell counts at 24 (±3) months, cells/μL (IQR) 327 352 (258–524) 387 (309–458) 340 (237–473) 0.483
Median increase from baseline in CD4 cell counts at 24 (±3) months,
cells/μL (IQR)
317 264 (184–374) 292 (220–384) 273 (178–383) 0.647
Major opportunistic infections, % 556 6.83 4.88 5.75 0.812
Paradoxical immune recovery syndrome, % 541 4.55 2.60 2.90 0.603
Malignancy, % 559 1.24 0.00 1.27 0.736
Non-AIDS defining conditions h, % 559 0.62 0.00 0.32 1.000
Death, % 559 3.10 0.00 1.58 0.206
Note: AZT = Zidovudine; CI = Confidence interval; D4T = Stavudine; EFV = Efavirenz; IQR = Interquartile range; NVP = Nevirapine; OBRs = Optimized background
regimens; SD = Standard deviation; TDF = Tenofovir; 3TC = Lamivudine.
aHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based regimens when they experienced allergic reactions to NVP-based regimens.
bHIV-1-infected patients who discontinued NVP first but continued use of the other NRTIs for a few days when they experienced allergic reactions to NVP-based
regimens.
cHIV-1-infected patients who were naïve to antiretroviral therapy and were never exposed to NVP before beginning EFV-based regimens.
dp-value represents the difference between the three groups (Simultaneous interruption, Staggered interruption, and Control).
ePatients who halted EFV-based regimens for fewer than 3 months were classified as having an EFV-based regimen interruption and remained in the study.
fVirological failure was defined as either (1) having two consecutive results of plasma HIV-1 RNA >400 copies/ml after 6 month of a EFV-based regimen or
(2) having plasma HIV-1 RNA >1,000 copies/ml plus having any genotypic resistance mutation to EFV-based regimen.
gVirological suppression was defined as having plasma HIV-1 RNA either: (1) having plasma HIV-1 RNA <50 copies/ml (based on RT-PCR using the COBAS Amplicor
HIV-1 Monitor Test Ver 1.5, Roche Molecular Systems Inc., Branchburg, NJ, USA),or (2) having plasma HIV-1 RNA <40 copies/ml (based on RT-PCR using the
COBASW AmpliPrep/COBASW TaqManW HIV-1 test, Roche Molecular Systems Inc., Branchburg, NJ, USA).
hNon-AIDS defining conditions included major cardiovascular, renal and hepatic disease outcomes as defined by the Strategies for Management of Antiretroviral
Therapy (SMART) Study Group [16].
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ure between the Simultaneous Interruption and Control
groups was 1.97 (0.62-6.38), p = 0.100. The relative risk
between the Simultaneous Interruption and Staggered
Interruption groups was 2.38 (0.32–105.75), p = 0.224.
The Staggered Interruption group displayed virological
outcomes comparable to those of the Control group.
There were imbalances in the three groups’ baseline
characteristics, such as age, sex, previous history of major
opportunistic infections, baseline CD4 cell count, fre-
quency of ARV administration, and history of EFV-based
regimen interruptions (Table 1 and Table 2). A stratified
analysis was performed to adjust for the effects of thesefactors on the primary outcome (virological failure). There
were no significant differences between the adjusted rela-
tive risk ratios and the crude relative risk ratios.
Overall, 12 of the 16 subjects (75%) who experienced
virological failure underwent genotypic resistance assays
prior to changing to other regimens (Simultaneous Inter-
ruption n =6, Staggered Interruption n = 1, and Control
n = 5). The mutations detected in these 12 subjects
included TAMs (n = 4), M184V mutations (n = 6), and
NNRTI-resistance mutations (n = 10). The incidence of
NNRTI-resistance mutations in the Simultaneous Inter-
ruption group was 8.1 cases/1,000 person-years, which
trended toward being higher than the incidences in the
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Control (3.74 cases/1000 person-years) groups. However,
these differences were not statistically significant. The
Y181C and G190A NNRTI-resistance mutations, which
are frequently related to the selective effect of NVP
[17,18], were identified in only one subject in each of the
Staggered Interruption and Simultaneous Interruption
groups.
At 24 months after EFV-based regimens, there were
440 patients in the cohort. Virological suppression at 24
(±3) months after receiving EFV-based regimens (per-
protocol analysis) was not significantly different among
the three groups (p = 0.411) (Table 2). However, there
were only 314 patients (71%) who had virological results
during this period, and patients who did not have viro-
logical results were counted as non-suppressed when we
analyzed for virological suppression.
Adverse events of EFV-based regimens
Table 3 presents the adverse events associated with EFV-
based regimens among the study cohort. There were 23
patients (4.1%) who were unable to tolerate EFV (Figure 1),
mainly due to either (a) EFV-induced central nervousTable 3 Adverse events of EFV-based regimens in eligible HIV
EFV-based regimens
Simultaneous Interruptiona
Total number, n 161
Significant clinical adverse eventse
Lipoatrophy/Lipodystrophy, % 47.2
Mitochondrial toxicityf, % 2.5
Severe anemia, % 3.1
Renal toxicity, n (%) 1 (0.6%)
CNS toxicity, n (%) 4 (2.5%)
Allergic reactions to EFV, n (%) 3 (1.9%)
Allergic reactions to NRTIs, n (%) 1 (0.6%)
≥ Grade 3 laboratory adverse eventsg




Note: CNS = Central nervous system; EFV = Efavirenz; NRTI = Nucleoside analogue r
aHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based re
bHIV-1-infected patients who discontinued NVP first but continued use of the other
regimens.
cHIV-1-infected patients who were naïve to antiretroviral therapy and were never ex
dp-value represents the difference between the three groups (Simultaneous interru
e Significant clinical adverse events was defined as clinical events that caused docto
fMitochondrial toxicity was diagnosed if a patient had both (1) serum lactate ≥ 2 m
peripheral neuropathy, and lactic acidosis.
gThese events were diagnosed based on the Division of AIDS Table for Grading the
hDiabetes mellitus defined as a new onset with medication initiation is indicated O
iTriglyceride >750 mg/dL.
jCholesterol >300 mg/dL.
keither AST or ALT ≥ 185 u/L.system toxicity (n = 10) or (b) EFV-induced allergic reac-
tions (n = 8).
Discussion
The current guidelines [2,19] recommend the use of a
staggered interruption strategy in patients who must
interrupt an NNRTI-based regimen. The duration of the
use of NRTIs after the discontinuation of the NNRTI
regimen ranged from 1 to 3 weeks [2,8,19]. However, the
optimal duration has not been determined.
In this study, the patients in the Staggered Interruption
group, who continued the use of 2 NRTIs for a median of
7 days after discontinuing NVP, had virological outcomes
comparable to those of the Control group (Figure 1 and
Table 2). These results are in accordance with a post-study
analysis of the Strategies for Management of Antiretroviral
Therapy (SMART) trial by Fox et al. [15]. Consequently, it
should be appropriate to use a staggered interruption
strategy if the NRTIs are to be continued for 7 days.
Among the HIV-infected patients who received an
NVP-based regimen for at least 2 weeks, the duration of
detectable NVP levels after discontinuation varied from 7
to 21 days [20,21]. Thus, patients who experience acute-1-infected patients (n = 559)






2 (2.4%) 5 (1.6%) 0.6293
1 (1.2%) 4 (1.3%) 0.816






gimens when they experienced allergic reactions to NVP-based regimens.
NRTIs for a few days when they experienced allergic reactions to NVP-based
posed to NVP before beginning EFV-based regimens.
ption, Staggered interruption, and Control).
rs to change or modify antiretroviral therapy.
mol/L, and (2) symptoms caused by NRTI toxicity such as lipoatrophy,
Severity of Adult and Pediatric Adverse Events (“DAIDS AE grading table”).
R uncontrolled DM despite medication modification.
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http://www.aidsrestherapy.com/content/10/1/4allergic reactions to an NVP-based regimen may acquire
NNRTI-resistant mutations if they simultaneously stop all
the drugs in the NVP-based regimen. A simultaneous
interruption strategy for discontinuing NNRTI-based regi-
mens is not recommended in the current DHHS guide-
lines [2]. In this study, there was a higher incidence of
virological failure and genotypic resistance mutations to
NNRTI in the Simultaneous Interruption group than in
the other groups. Thus, a simultaneous interruption stra-
tegy is not advisable.
The median follow-up time duration of the Simulta-
neous Interruption group was significantly longer than
those of the other groups (p<0.001) (Table 1). This
result may have been influenced by a general recom-
mendation in the DHHS guidelines (the November 3,
2008 version) [11] that a staggered interruption strategy
should be employed to prevent NNRTI resistance after
discontinuing NNRTI-based regimens. In this study,
there were 141 (88%) patients in the Simultaneous
Interruption group who began an EFV-based regimen
prior to November 3, 2008.
The current guidelines recommend that patient
plasma HIV-1 RNA levels and CD4 cell counts be moni-
tored regularly, at least twice per year [1,2,22]. Never-
theless, the plasma HIV-1 RNA levels of 21% of the
cohort were assayed less than once per year. Thus, the
final evaluation was designed to assess the laboratory
data of the patients who remained in the cohort through
the end of study. The evaluation may have produced a
more accurate diagnosis of laboratory-related events
and data, such as virological outcomes and laboratory
adverse events.
In the beginning of the study, d4T/3TC was commonly
administered to our patients (Figure 1) because TDF was
not available in our hospital until January 2007.
The low incidence of virological failure may have
resulted from the removal from the cohort of patients
who were lost to follow-up (e.g., either a documented
discontinuation of an EFV-based regimen for more than
3 months or a failure to attend a follow-up examination
at the hospital for longer than 3 months after the ori-
ginal appointment date). These patients generally exhi-
bited low compliance with ARV therapy, which is
associated with virological failure [23,24].
This study had the following limitations: (a) a retro-
spective design; (b) a non-randomized design; (c) some
incomplete data (including CD4 cell counts, plasma
HIV-1 RNA levels, and the results of genotypic resis-
tance assays); (d) a follow-up loss of 9.5%; and (e) the
frequent use, in the beginning of the study, of NRTI
drugs such as d4T/3TC that are not preferred NRTIs
under the current guidelines (1, 2, 22). These limitations
should be carefully considered when interpreting the
data from this study.Conclusion
In our cohort of patients who experienced acute allergic
reactions to first-line NVP-based therapy and later began
an EFV-based regimen, the virological outcomes of the
Staggered Interruption group (who continued 2 NRTIs
for 7 days after discontinuing NVP) did not differ from
those of the Control group (who began an EFV-based
regimen as their initial treatment). However, the viro-
logical failure in the Simultaneous Interruption group
was possibly higher than that in the Staggered Interrup-
tion and Control groups.
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